Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials

dc.contributor.authorAygoren-Pursun, Emel
dc.contributor.authorCohn, Danny M.
dc.contributor.authorAgmon-Levin, Nancy
dc.contributor.authorBanerji, Aleena
dc.contributor.authorBernstein, Jonathan A.
dc.contributor.authorBusse, Paula
dc.contributor.authorCancian, Mauro
dc.contributor.authorDe Castro, Eunice Dias
dc.contributor.authorFarkas, Henriette
dc.contributor.authorGrivcheva-Panovska, Vesna
dc.contributor.authorHagin, David
dc.contributor.authorHakl, Roman
dc.contributor.authorHonda, Daisuke
dc.contributor.authorKessel, Aharon
dc.contributor.authorKinaciyan, Tamar
dc.contributor.authorKurowski, Marcin
dc.contributor.authorLi, H. Henry
dc.contributor.authorLleonart Bellfill, Ramon
dc.contributor.authorLonghurst, Hilary J.
dc.contributor.authorLumry, William R.
dc.contributor.authorMagerl, Markus
dc.contributor.authorMartinez-Saguer, Inmaculada
dc.contributor.authorMelamed, Isaac
dc.contributor.authorPsarros, Fotis
dc.contributor.authorSavic, Sinisa
dc.contributor.authorSoteres, Daniel F.
dc.contributor.authorStaevska, Maria
dc.contributor.authorStobiecki, Marcin
dc.contributor.authorWedner, H. James
dc.contributor.authorZanichelli, Andrea
dc.contributor.authorHao, James
dc.contributor.authorPatil, Ketan
dc.contributor.authorIverson, Matthew
dc.contributor.authorOwiredu-Yeboa, Samuel
dc.contributor.authorSmith, Michael D.
dc.contributor.authorYea, Christopher M.
dc.contributor.authorAudhya, Paul K.
dc.contributor.authorRiedl, Marc A.
dc.contributor.authorKiani-Alikhan, Sorena
dc.contributor.authorMaurer, Marcus
dc.date.accessioned2026-10-19T12:03:57Z
dc.date.available2026-10-19T12:03:57Z
dc.date.issued2026-07-01
dc.date.updated2026-10-19T11:37:32Z
dc.description.abstractBackground: Clinical trial designs evaluating on-demand therapies for hereditary angioedema attacks have evolved in response to changes in treatment guidelines. Sebetralstat, an oral plasma kallikrein inhibitor, was evaluated in 2 randomized, placebo-controlled clinical trials, which instructed early treatment of attacks with no minimum severity requirement. Objective: Characterize the efficacy and safety of sebetralstat by pooling data from phase 2 and 3 trials. Methods: This pooled analysis included participants (phase 2, aged >= 18 years; phase 3, aged >= 12 years) who received >= 1 dose of study drug (phase 2, sebetralstat 600 mg or placebo; phase 3, sebetralstat 300 mg or 600 mg, or placebo). Efficacy outcomes included times to beginning of symptom relief within 12 h, reduction in severity within 12 h, and complete attack resolution within 24 h. P values were not adjusted for multiplicity. Results: 377 attacks were treated: 87 with sebetralstat 300 mg; 151 with sebetralstat 600 mg; 139 with placebo. Median (interquartile range) time to treatment was 32.5 min (8.0-94.0). Baseline severity was rated as "Mild" (46.2%), "Moderate" (40.6%), or "Severe"/"Very Severe" (12.7%). Compared with placebo, time to beginning of symptom relief was faster with sebetralstat (300 mg; 600 mg [P = 0.0001; P < 0.0001]), as was reduction in severity (P = 0.0038; P < 0.0001) and complete attack resolution (P = 0.0021; P < 0.0001). Median time to beginning of symptom relief was 1.6 h (0.8-7.0) and 1.8 h (1.0-4.3) with sebetralstat 300 mg and 600 mg, respectively, and 8.3 h (1.5 to >12) with placebo. Sebetralstat had a safety profile comparable to placebo. Conclusion: Across phase 2 and 3 clinical trials, sebetralstat enabled early treatment, provided effective symptom relief versus placebo, and was well tolerated, regardless of attack location or baseline severity.
dc.format.extent101401
dc.format.mimetypeapplication/pdf
dc.identifier.issn1939-4551
dc.identifier.urihttps://hdl.handle.net/2445/232133
dc.language.isoeng
dc.publisherElsevier Inc.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.waojou.2026.101401
dc.relation.isformatofVersió postprint del document: https://doi.org/10.1016/j.waojou.2026.101401
dc.relation.ispartofAygören Pürsün,E;Cohn,DM;Agmon Levin,N;Banerji,A;Bernstein,JA;Busse,P;Cancian,M et al, Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials, World Allergy Organ. J., 2026;19(7):doi:10.1016/j.waojou.2026.101401,
dc.relation.urihttps://doi.org/10.1016/j.waojou.2026.101401
dc.rights(c)ELSEVIER
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleSebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Sebetralstat fon on demand treatment_L.pdf
Mida:
4.38 MB
Format:
Adobe Portable Document Format